Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Phase I consists of a single-arm safety lead-in study evaluating the safety and preliminary efficacy of the investigational regimen. If predefined safety criteria are met, the study proceeds to a phase II randomized controlled trial comparing induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunot

Trial Details

NCT ID

NCT07632365

Phase

PHASE1 / PHASE2

Sponsor

Shanghai Chest Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Induction chemoimmunotherapy
Concurrent chemoradiotherapy (cCRT)
consolidation immunotherapy

Locations (sample)

Shanghai, Xuhui, China|31.22222,121.45806

Key Eligibility Criteria

Age \>18 years, male or female, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
Unresectable stage III NSCLC (according to the 8th edition of the AJCC staging system).
No prior exposure to any other anti-tumor therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →